36 results about "Detrusor muscle" patented technology

Electrical stimulation of specific sensory nerves to control the filling and / or emptying of the urinary bladder. A wireless, injectable microstimulator is implanted into the soft tissues through which the sensory nerves pass, but where they are not normally accessible by conventional open surgical implantation of conventional electrical stimulators or electrodes with leads. In males, the dorsal penile nerves 6 are stimulated by a microstimulator injected into the dorsal quadrant of the penis. The activity induced in these nerves cause the spinal cord to generate reflex responses that result in relaxation of the detrusor muscle, increasing bladder capacity and preventing incontinence as a result of inappropriate bladder contractions. The sensory nerves, such as urethral afferents 4, supplying the urethra are stimulated by a microstimulator implanted into the corpus of the penis, adjacent to the urethra. The activity induced in the urethral afferents 4 cause the spinal cord to generate reflex responses that result in contractions of the detrusor muscle and relaxation of the sphincter 5, emptying the bladder.

This invention relates to tetrahydro-naphthalene and urea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The tetrahydro-naphthalene and urea derivatives of the present invention have vanilloid receptor (VR1) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urological diseases or disorders, such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor overactivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, and inflammatory disorders such as asthma and chronic obstructive pulmonary (or airways) disease (COPD).

Provided herein are methods for the treatment of bladder dysfunction, including detrusor hyperreflexia and detrusor external sphincter dyssynergia, fecal incontinence, and / or sexual dysfunction in an individual via the use of stably expressed light-responsive opsin proteins capable of selective hyperpolarization or depolarization of the neural cells that innervate the muscles responsible for physiologic functioning of urinary bladder, external urinary sphincter, external anal sphincter, and the male and female genitalia.

A method is provided for using α2δ subunit calcium channel modulators or other compounds that interact with the α2δ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and / or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, α2δ subunit calcium channel modulators include GABA analogs, e.g., gabapentin and pregabalin, fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.

The invention relate to the demonstration herein that it is feasible to use a transvaginal NIRS probe to interrogate functioning urological tissues, such as the urethral sphincter, the bladder detrusor muscle, and pelvic floor musculature, to obtain clinically relevant information. The present invention accordingly provides methods and devices for transvaginal monitoring or imaging of the urological tissues, such as the urethral sphincter and / or the bladder, and / or pelvic floor musculature, using NIRS.

Method and device for the sensing of the electromyographic activity of an individual's bladder detrusor muscle, where an elongated electrode is inserted through the individual's urethra, so that the proximal end of the electrode becomes positioned in the bladder, and the bladder is charged with a fluid having electrical conductivity, and the electrical potential of the detrusor muscle, mediated by the fluid, is sensed by the electrode.

Since a compound represented by formula (I) wherein all of the symbols are the same as defined in the specification, a salt thereof, a solvate thereof, a prodrug thereof, a mixture with a diastereomer thereof in an arbitrary ratio, or a cyclodextrin clathrate thereof have a contracting activity of bladder detrusor and a relaxing activity of urethral sphincter, they can ameliorate bladder contraction dysfunction and / or urethral relaxation dysfunction, and for example, are effective for underactive bladder. Additionally, the compound of the present invention has little risk of side effects on the urinary system, the circulatory system and the digestive system, and exhibits excellent pharmacokinetics, such as oral absorbability etc. Therefore, the compound of the present invention is useful as a superior agent for preventing, treating and / or ameliorating underactive bladder.

The present invention relates to lower urinary dysfunctions and more particularly to an electronic stimulator implant and method to improve bladder voiding and prevent bladder hyperreflexia. There is provided an electronic stimulator implant for which comprises a tonicity signal generator generating a tonicity signal which prevents bladder hyperreflexia combined with a voiding signal generator generating a voiding signal for voiding the bladder. The implant is connected to an end of an electrode, and the second end thereof is connected to a sacral nerve. When the voiding key (or switch) is activated, the voiding signal is generated which activates detrusor muscle contraction, causing bladder voiding. The voiding may be achieved without dyssynergia, by activating detrusor muscle contraction without activating external urethral sphincter contraction. The tonicity signal may be provided intermittently. The implant may be activated by a manually activated external controller.

This invention relates to bicyclic amide, carbamate or urea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The bicyclic amide, carbamate or urea derivative of the present invention has vanilloid receptor (VR1) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urological diseases or disorders, such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor oeractivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, and inflammatory disorders such as asthma and chronic obstructive pulmonary (or airways) disease (COPD).

The invention discloses a bladder activity assisting device and an application method thereof. The device comprises a shrinkage film, a power device and a receptor. The shrinkage film is arranged in agap between a bladder detrussing muscle layer and a serosa layer. The receptor is attached to a detrusor muscle layer. The receptor is coupled with the power device. The power device is linked with the shrinkage film. The shrinkage film comprises a fixed film and an expansion film. The edges of the fixed film and the expansion film are fixedly connected with each other. A power liquid is filled in a containing space. The power device comprises a storage cavity used for storing the power liquid and a power pump arranged in the storage cavity. According to the bladder activity assisting devicedisclosed by the invention, through the arrangement of the shrinkage film, the power device and the receptor, the situation that the urine in the bladder is full of urine can be effectively and timelysensed by the receptor. After that, the power device drives the shrinkage film to shrink so as to assist in promoting the contraction and the urination of the bladder detrusor muscle.

The invention relates to a device and treatment system for treating overactive bladder. The device comprises one or more ultrasonic generators for generating low intensity pulse ultrasonic waves and acontroller, and the controller is in signal connection with the ultrasonic generators and is used for controlling the ultrasonic generators to apply low intensity pulse ultrasonic waves to a bladderto be treated. According to the technical scheme, low intensity pulse ultrasonic waves are used for stimulating the proliferation and differentiation of smooth muscle cells and repair of nerve cells;the ultrasonic treatment device has a promoting effect on non-coordination of detrusor muscles of the bladder and muscles for controlling and relieving and the recovery of abnormal contraction functions of the muscles of the bladder, the treatment is non-intrusive and painless, a good effect is achieved by the low intensity pulse ultrasonic waves with very low energy, and the treatment effect is obvious.

Since a compound represented by formula (I) wherein all of the symbols are the same as defined in the specification, a salt thereof, a solvate thereof, a prodrug thereof, a mixture with a diastereomer thereof in an arbitrary ratio, or a cyclodextrin clathrate thereof have a contracting activity of bladder detrusor and a relaxing activity of urethral sphincter, they can ameliorate bladder contraction dysfunction and / or urethral relaxation dysfunction, and for example, are effective for underactive bladder. Additionally, the compound of the present invention has little risk of side effects on the urinary system, the circulatory system and the digestive system, and exhibits excellent pharmacokinetics, such as oral absorbability etc. Therefore, the compound of the present invention is useful as a superior agent for preventing, treating and / or ameliorating underactive bladder.

The invention relate to the demonstration herein that it is feasible to use a transvaginal NIRS probe to interrogate functioning urological tissues, such as the urethral sphincter, the bladder detrusor muscle, and pelvic floor musculature, to obtain clinically relevant information. The present invention accordingly provides methods and devices for transvaginal monitoring or imaging of the urological tissues, such as the urethral sphincter and / or the bladder, and / or pelvic floor musculature, using NIRS.

The present invention provides a compound that can be used as an MC4 receptor agonist. The inventors study MC4 receptor agonists, and confirm that a piperazine derivative has an action, thereby perfecting the present invention. Specifically, this piperazine derivative has an MC4 receptor agonist action and can be used as an agent for the prevention and / or treatment of bladder and urinary tract diseases, especially underactive bladder, hypotonic bladder, noncontracting bladder, detrusor muscle hypoactivity, neurogenic bladder, urethral relaxation failure, detrusor-external sphincter incoordination, and dysuria in benign prostatic hyperplasia.

To provide a compound useful as an MC4 receptor agonist. The present inventors have made studies on MC4 receptor agonists. As a result, it is confirmed that a piperazine derivative has an MC4 receptoragonist activity, which leads to the accomplishment of the present invention. The piperazine derivative according to the present invention has an MC4 receptor agonist activity, and therefore can be used as a prophylactic or therapeutic agent for disturbance of urination in bladder and urinary tract diseases, particularly underactive bladder, hypotonic bladder, acontractile bladder, detrusor underactivity, neurogenic bladder, urethral relaxation failure, detrusor-sphincter dyssynergia and prostatic hyperplasia.

The application provides a combination medicine, which comprises Cynomorium extract and Phellodendron chinensis extract, and the weight ratio of a single administration of the Cynomorium extract to the single administration of the Phellodendron Phellodendri extract is 1:(1.0-1.5) . The application also provides the use of the combined medicament in the preparation of a medicament for preventing and / or treating benign prostatic hyperplasia and lower urinary tract symptoms. The combination drug provided by the application can inhibit the enlargement of the prostate volume, reduce the prostate index and bladder index, improve the tissue lesions of the prostate and bladder, reduce the level of estradiol / testosterone, reduce the maximum voiding pressure, and increase the detrusor muscle. The muscle tension can be used to prevent and / or treat benign prostatic hyperplasia and lower urinary tract symptoms, and then be used to prepare a medicament for preventing and / or treating benign prostatic hyperplasia and lower urinary tract symptoms. The combined medicament of the present application has a synergistic effect, is suitable for long-term treatment, and has a good clinical application prospect.

The invention discloses a bladder activity assisting device and an application method thereof. The device comprises a shrinkage film, a power device and a receptor. The shrinkage film is arranged in agap between a bladder detrussing muscle layer and a serosa layer. The receptor is attached to a detrusor muscle layer. The receptor is coupled with the power device. The power device is linked with the shrinkage film. The shrinkage film comprises a fixed film and an expansion film. The edges of the fixed film and the expansion film are fixedly connected with each other. A power liquid is filled in a containing space. The power device comprises a storage cavity used for storing the power liquid and a power pump arranged in the storage cavity. According to the bladder activity assisting devicedisclosed by the invention, through the arrangement of the shrinkage film, the power device and the receptor, the situation that the urine in the bladder is full of urine can be effectively and timelysensed by the receptor. After that, the power device drives the shrinkage film to shrink so as to assist in promoting the contraction and the urination of the bladder detrusor muscle.

The invention discloses a power device for a bladder activity auxiliary device. The power device comprises a storage cavity and a power pump, the storage cavity is used for storing highly-compressed power gas, the power pump is arranged in the storage cavity, a circulation opening is formed in the wall of the storage cavity, connected to an external air bag through a guide pipe and communicated with the air bag each other, straining signals inputted by the outside of the power pump drives power gas to be injected into the air bag, so that the air bag is expanded towards a detrusor to extrude and contract the detrusor, the storage cavity comprises an elastic air storage bag, one surface of the elastic air storage bag wraps the outer wall of a bladder, and the circulation opening is an opening of the air storage bag. According to the power device for the bladder activity auxiliary device, the storage cavity is set into a contracted air storage bag, the volume of the storage cavity is effectively and uniformly dispersed onto the outer wall of the bladder by the air storage bag, excessive space of a pelvic cavity cannot be occupied, and the power device is effectively applicable to auxiliary contraction of the bladder detrusor.

The invention relates to the field of biomedical materials, in particular to a magnetic composite mesh for assisting urination and a preparation method of the magnetic composite mesh. The magnetic composite mesh comprises magnetized ferromagnetic particles and a composite mesh; the magnetized ferromagnetic particles are embedded into grids of the composite mesh to form a flexible magnetic control covering layer; the flexible magnetic control covering layer is attached to an outer membrane layer on the inner side of the bladder and used for serving as an artificial detrusor muscle capable of applying normal urination pressure under the condition of a gradient magnetic field. The method comprises the following steps: respectively obtaining non-magnetized ferromagnetic particles and a composite mesh; the ferromagnetic particles are magnetized, and magnetized ferromagnetic particles are obtained after magnetization; bonding the magnetized ferromagnetic particles and the composite mesh, and then performing first curing to obtain a magnetic composite mesh capable of applying normal urination pressure; by adopting the magnetic composite mesh sheet comprising the magnetized ferromagnetic particles and the composite mesh sheet, the pressure of the artificial detrusor muscle can be effectively ensured to accord with the urination pressure of the bladder of a human body.

Provided can be used as MC 4 Agonist compounds. MC 4 Receptor agonists were studied and it was confirmed that piperazine derivatives have MC 4 receptor agonist action, thus completing the present invention. The piperazine derivatives of the present invention have MC 4 Receptor agonist action, can act as bladder, urological disorders, especially hypoactive bladder, hypotonic bladder, non-contracting bladder, detrusor hypoactivity, neurogenic bladder, urethral insufficiency, detrusor-extraurethral Prophylactic or therapeutic agent use for sphincter dyssynergia and voiding disorder in prostatic hypertrophy.

This invention relates to tetrahydro-quinolinylurea derivatives and salts thereof which are useful as active ingredi- ents of pharmaceutical preparations. The tetrahydro-quinolinylurea derivative of the present invention has vanilloid receptor (VR I) C antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for =the treatment of urological diseases or disorders, such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor oeractivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, and inflammatory disorders such as asthma and chronic obstructive pul- monary (or airways) disease (COPD).

The invention provides application of norisoboldine in preparing drugs for preventing and / or treating a bladder smooth muscle dysfunction, and belongs to the technical field of treatment of the bladder smooth muscle dysfunction. The norisoboldine has a very good and obvious regulating function on a bladder smooth muscle function, can lower the contraction ability of detrusor, obviously reduces a contraction response caused to alpha, beta-methylene adenosine 5'-triphosphate (ATP), CCh and KCl by the detrusor, can further obviously reduce contraction caused by electrical field stimulation (EFS),can be used for treating overactive bladder, and can also be used for treating various diseases including uroclepsia, hyperuresis and the like.

The present invention provides methods of alleviating one or more signs or symptoms of smooth muscle diseases. Compositions of the disclosure may include a plasmid vector containing a nucleic acid that encodes a Maxi-K channel peptide. Compositions of the disclosure may be administered intradetrusorally to at least two or more sites at a single unit dose.

The present invention provides the ability to be used as MC 4 Compounds used as agonists. MC 4 Research on receptor agonists was carried out, and the effect of piperazine derivatives was confirmed, thereby completing the present invention. That is, the piperazine derivatives of the present invention have MC 4 Receptor agonist action, can be used as bladder and urinary tract diseases, especially hypoactive bladder, hypotonic bladder, non-contracting bladder, detrusor hypoactivity, neurogenic bladder, urethral insufficiency, detrusor extraurethral Prophylactic and / or therapeutic agent use for sphincter dyssynergia and voiding disorders in benign prostatic hypertrophy.

The invention provides application of norisoboldine in preparing drugs for preventing and / or treating a bladder smooth muscle dysfunction, and belongs to the technical field of treatment of the bladder smooth muscle dysfunction. The norisoboldine has a very good and obvious regulating function on a bladder smooth muscle function, can lower the contraction ability of detrusor, obviously reduces a contraction response caused to alpha, beta-methylene adenosine 5'-triphosphate (ATP), CCh and KCl by the detrusor, can further obviously reduce contraction caused by electrical field stimulation (EFS),can be used for treating overactive bladder, and can also be used for treating various diseases including uroclepsia, hyperuresis and the like.

The present invention provides methods of alleviating one or more signs or symptoms of smooth muscle diseases. Compositions of the disclosure may include a plasmid vector containing a nucleic acid that encodes a Maxi-K channel peptide. Compositions of the disclosure may be administered intradetrusorally to at least two or more sites at a single unit dose.

The invention discloses a traditional Chinese medicine for treating benign prostatic hyperplasia with kidney deficiency and blood stasis and a preparation method for bladder detrusor dysfunction. The traditional Chinese medicine includes the following raw materials: Cuscuta 15-30g, Cornus officinale 14-16g, Golden Cherry 14-16g, burnt dragon bone 20-30g, leek seeds 15-20g, astragalus 30-45g, amber 2.5-3.5g, blanched leech 3-5g, Aphrodisiac 15-20g, mulberry octopus 10-15g, soybean herb 20‑30g, Sichuan Achyranthes 14‑16g. The invention is made of pure natural raw materials and Chinese medicines. Various medicines are organically coordinated, synergistic, reasonably formulated, rich in raw materials, simple in method, convenient to take, good in curative effect and low in cost. It is an ideal method for treating benign prostatic hyperplasia and bladder pressure. A major innovation in the treatment of urinary muscle dysfunction.

The invention provides a combined medicine which comprises a cynomorium songaricum extract and a cortex phellodendri extract, and the weight ratio of single medication of the cynomorium songaricum extract to single medication of the cortex phellodendri extract is 1:(1.0-1.5). The invention further provides application of the combined medicine in preparation of medicine for preventing and / or treating benign prostatic hyperplasia and lower urinary tract symptoms. The combined medicine provided by the invention can inhibit the increase of the prostate volume, reduce the prostate index and the bladder index, improve the tissue lesions of the prostate and the bladder, reduce the estradiol / testosterone level, reduce the maximum urination pressure and increase the tension of the detrusor muscle strip, so that the combined medicine can be used for preventing and / or treating prostatic hyperplasia and lower urinary tract symptoms, and the combined medicine is further used for preparing medicines for preventing and / or treating benign prostatic hyperplasia and lower urinary tract symptoms. The combined medicine disclosed by the invention has a synergistic effect, is suitable for long-term treatment and has a good clinical application prospect.